Effect of mTOR Inhibitor and Octreotide LAR on the Vascularization of Hepatic Metastases of Non-Pancreatic NETs: Preliminary Semi-Quantitative Dynamic MRI Assessment
#322
Introduction: mTOR inhibitor Everolimus is a promising treatment in advanced NET. Its mechanisms include an antiangiogenic effect. Dynamic-enhanced MRI (D-MRI) enables the in vivo evaluation of tumoral perfusion.
Aim(s): To correlate parameters of D-MRI and PFS of patients enrolled in the RADIANT-2 phase III trial comparing Octreotide LAR plus Everolimus or placebo.
Materials and methods: Nine patients with liver metastasis from advanced non-pancreatic NET included in RADIANT-2 receiving Everolimus plus Octreotide LAR. Liver MRI at baseline and three months. On D-MRI T1w sequences, signal and contrast to-noise, relative enhancement for each MRI sequences and the peak of maximum enhancement measured in 42 metastases and correlated to the PFS.
Conference: 8th Annual ENETSConcerence (2011)
Presenting Author:
Authors: Pham C, E. B, C. C, J. G, F. B,
Keywords: neuroendocrine tumor, mTOR, everolimus, octreotide, vascularisation, MRI,
To read the full abstract, please log into your ENETS Member account.